Analysts expect Dova Pharmaceuticals Inc (NASDAQ:DOVA) to post ($0.72) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Dova Pharmaceuticals’ earnings, with estimates ranging from ($0.77) to ($0.66). Dova Pharmaceuticals reported earnings per share of ($0.36) during the same quarter last year, which would indicate a negative year-over-year growth rate of 100%. The company is scheduled to announce its next quarterly earnings results on Thursday, February 21st.
On average, analysts expect that Dova Pharmaceuticals will report full year earnings of ($2.63) per share for the current fiscal year, with EPS estimates ranging from ($2.69) to ($2.57). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.06) per share, with EPS estimates ranging from ($2.78) to ($1.04). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Dova Pharmaceuticals.
Dova Pharmaceuticals (NASDAQ:DOVA) last released its earnings results on Thursday, November 8th. The company reported ($0.69) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.12. The company had revenue of $2.93 million for the quarter, compared to analyst estimates of $2.66 million.
DOVA traded up $0.06 on Friday, hitting $14.48. 151,289 shares of the company were exchanged, compared to its average volume of 176,013. Dova Pharmaceuticals has a twelve month low of $14.09 and a twelve month high of $37.00. The stock has a market capitalization of $406.70 million, a price-to-earnings ratio of -10.34 and a beta of 0.71. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.50 and a quick ratio of 7.40.
Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its position in shares of Dova Pharmaceuticals by 0.8% during the 3rd quarter. BlackRock Inc. now owns 1,154,232 shares of the company’s stock worth $24,204,000 after acquiring an additional 9,312 shares in the last quarter. Nexthera Capital LP boosted its position in shares of Dova Pharmaceuticals by 25.2% during the 3rd quarter. Nexthera Capital LP now owns 1,026,906 shares of the company’s stock worth $21,534,000 after acquiring an additional 206,558 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Dova Pharmaceuticals by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 619,604 shares of the company’s stock worth $12,993,000 after acquiring an additional 14,985 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Dova Pharmaceuticals by 12.7% during the 2nd quarter. Wells Fargo & Company MN now owns 380,455 shares of the company’s stock worth $11,383,000 after acquiring an additional 42,819 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its position in shares of Dova Pharmaceuticals by 95.6% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 233,200 shares of the company’s stock worth $4,890,000 after acquiring an additional 114,000 shares in the last quarter. 37.14% of the stock is owned by institutional investors and hedge funds.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Further Reading: How Do I Invest in Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.